Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck’s Solid Quarter Doesn’t Soothe Seagen M&A Watchers

No Deal Was Announced, To The Chagrin Of Investors

Executive Summary

Keytruda- and Gardasil-driven revenue growth exceeded forecasts and Merck expects to keep the PD-1 blockbuster cash coming with earlier-stage indications and a potential subcutaneous formulation.

You may also be interested in...



MSD India Chief On The Now, Next For Januvia, Gardasil And Keytruda’s Ascent

MSD India managing director Rehan Khan talks to Scrip about price adjustments for Januvia and the brand’s strong physician recall amid a tsunami of competition post loss of exclusivity, as also plans for Gardasil, which faces upcoming competition from Indian vaccines star Serum Institute. He also signals huge strides made by Keytruda, now the top cancer therapy in the country.

US Pharmas Display Defensive Mettle But Headwinds Mount

US big pharma manufacturers generally delivered sales and earnings growth in the second quarter and reaffirmed guidance despite currency headwinds; US drug pricing legislation could present a tipping pressure point.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: planned US drug pricing legislation in focus; solid quarter but no Seagen announcement for Merck & Co; AbbVie’s Gonzalez sounds alarm over US pricing legislation; Alnylam ready to expand in amyloidosis; and Boehringer Ingelheim on global Jardiance strategy.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146790

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel